Immediate Impact

74 standout
Sub-graph 1 of 21

Citing Papers

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
2024 Standout
18 intermediate papers

Works of F. Norwood being referenced

Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group
2013
The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome
2010

Author Peers

Author Last Decade Papers Cites
F. Norwood 182 35 14 58 38 8 293
Jo Stevens 143 19 6 46 11 15 273
Paola Vázquez-Cárdenas 63 22 38 108 66 11 318
M Salmon 52 36 6 32 15 8 257
Charles M. Harper 130 58 3 132 22 11 325
Vittorio Gatto 73 21 19 102 17 12 288
J B Peiris 138 48 22 25 39 14 271
S. Goodburn 91 137 158 99 42 12 332
Eva Eliassen 108 25 3 26 11 9 305
Deepa Bhattarai 55 8 12 111 56 12 306
Šarūnas Tamašauskas 43 7 26 46 38 14 302

All Works

Loading papers...

Rankless by CCL
2026